Trials / Completed
CompletedNCT02857907
Anti-thymocyte Globulin-induced Immune Senescence
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 97 (actual)
- Sponsor
- Centre Hospitalier Universitaire de Besancon · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The aim of the study is to investigate the impact of Anti-Thymocyte Globulin (ATG) on immune senescence. Markers of immune senescence expression is assessed in a prospective cohort of renal transplant recipients the day of transplantation and one year after renal transplantation.
Detailed description
The anti-thymocyte globulin (ATG) are used in the prevention and treatment of acute rejection in organ transplantation. They are at the origin of a brutal CD4 lymphocyte depletion followed by a gradual recovery of the lymphocyte pool. Nevertheless, CD4 lymphopenia can persist in some patients. SIGAL study aims to characterize the immune responses of lymphopenic patients (after administration of ATG) in order to identify possible similarities with immunosenescence.The immunosenescence is a complex and profound remodeling of the immune system during life. It is mainly due to thymic involution and repeated antigenic stimulation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Blood sample | A blood sample is performed one year after kidney transplantation. |
Timeline
- Start date
- 2010-04-01
- Primary completion
- 2013-01-01
- Completion
- 2013-01-01
- First posted
- 2016-08-05
- Last updated
- 2016-08-05
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT02857907. Inclusion in this directory is not an endorsement.